Clinical Cancer Research Holland2
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Thomas, R.
Right arrow Articles by Vessella, R. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Thomas, R.
Right arrow Articles by Vessella, R. L.
Clinical Cancer Research Vol. 6, 1140-1149, March 2000
© 2000 American Association for Cancer Research

Molecular Oncology, Markers, Clinical Correlates

Differential Expression of Osteonectin/SPARC during Human Prostate Cancer Progression1

Regi Thomas2, Lawrence D. True, James A. Bassuk, Paul H. Lange and Robert L. Vessella

Departments of Urology [R. T., J. A. B., P. H. L., R. L. V.] and Pathology [L. D. T.], University of Washington, Seattle, Washington 98195


   ABSTRACT
Top
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
The precise mechanism(s) involved in invasion and metastasis of prostate cancer (CaP) is poorly understood. Osteonectin [ON (also known as SPARC or BM-40)] is an antiadhesive protein known to be involved in cell-matrix interactions, migration, and angiogenesis. In this report, we studied the expression of ON in human prostate cell lines, primary tumors, and metastatic foci of CaP. Reverse transcription-PCR and nonradioactive in situ hybridization (ISH) techniques were used to determine ON gene expression. Immunohistochemistry was carried out using the polyclonal antibody LF37 and/or the monoclonal antibody ON-mAb. Low to moderate levels of ON mRNA and protein were observed in glandular epithelial cells of normal tissue as well as a few primary CaPs. However, high levels of ON mRNA and protein were observed in most of the CaP metastatic foci, both osseous and nonosseous. This correlated well with our findings that multiple different CaP cell lines including four CaP cell lines derived from metastases show high levels of ON gene expression. Furthermore, ISH analyses and cell-specific reverse transcription-PCR evaluation showed that both the luminal and basal cells express the ON gene. We conclude that the differential pattern of ON expression suggests that it may play an important role in the progression of CaP.


   INTRODUCTION
Top
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
The ability of cancer cells to invade and metastasize from the primary site is a hallmark of malignancy. Such is the intolerant nature of this process that patients with distant metastatic disease are almost invariably incurable. Thus, it is imperative to understand the cellular and molecular mechanisms of tumor dissemination to develop novel therapies for intervention. The acquisition of invasive and metastatic potential involves complex cell-cell and cell-ECM3 interactions. Cell surface glycoproteins with their matrix ligand have been implicated in this process. ON also known as BM-40 or SPARC, is a secreted glycoprotein that modulates the interaction of cells with the ECM. Other members of the ON family that have a similar basic structure to ON include hevin (1) , SC1 (2) , QR-1 (3) , follistatin-like protein (TSC-36; Ref. 4 ) and testican (5) . Of these proteins, the 232 COOH-terminal amino acids of hevin (human SC1) show a 62% identity to the homologous portion of human SPARC. Although the specific role of ON is elusive, the high degree of evolutionary conservation of this protein among different species suggests that ON has an important physiological role (6, 7, 8, 9) . Although initial studies associated this protein with bone mineralization, recent studies indicate that this protein has pleiotropic effects on biological functions as diverse as proliferation (10, 11, 12) , morphogenesis (7 , 13) , tissue remodeling (14 , 15) , migration (16) , and angiogenesis (10 , 17 , 18) . The phenotype of SPARC-null mice is such that they develop age-related cataracts due to aberrant differentiation of lenticular epithelial cells and incomplete fiber cell differentiation (19) .

A variety of in vitro studies have shown that secretion of ON affects cell morphology by reducing the number of focal contacts and blocking the adhesion of cells to their substratum or to neighboring cells (9 , 20) . ON expression is up regulated in transformed cells (7) . Increased expression is also associated with the neoplastic progression of several human tumor types (21, 22, 23, 24, 25, 26, 27, 28) . Suppression of ON expression using antisense RNA significantly decreased the tumorigenicity of human melanoma cells by reducing their invasive and adhesive properties (26) . To date, however, there are no detailed studies on ON expression in prostatic tissue. The aim of the current study was to analyze ON mRNA and protein expression in malignant as well as normal prostatic tissues, CaP cell lines, and immortalized prostate epithelial cell lines.


   MATERIALS AND METHODS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Cell Lines.
Unless otherwise specified, all of the human CaP cell lines were grown in RPMI 1640 (Life Technologies, Inc., Gaithersburg, MD) supplemented with 10% fetal bovine serum. Cultures were maintained at 37°C in a 5% CO2 humidified incubator. The cell types used in this study were human CaP cell lines including DU 145 (29) , parental PC-3 (30) , parental LNCaP (31) , VeCaPs4 (a gift from Dr. K. Pienta, University of Michigan, MI), and prostate epithelial cell line PZ-HPV-7 (32) . Other cell lines include sublines of LNCaP (32) , the C4, C4-2, and C4-2b, and sublines of PC-3, N-PC3 (noninvasive), and B-PC3 (invasive; both are gifts from Dr. M. Stearns, Medical College of Pennsylvania, Philadelphia, PA). C4 is an androgen-dependent cell line derived from mice that were coinoculated with LNCaP and the human osteosarcoma cell line MS. C4-2 is a second-generation cell line derived from C4, and it is androgen independent. C4-2b is another subline derived from the bone metastasis of a mouse that was inoculated with C4-2. VeCaps is a CaP cell line derived from a spine metastasis and grown in DMEM supplemented with 10% fetal bovine serum. PZ-HPV-7 is a human papilloma virus immortalized cell line derived from normal human prostate epithelial cells and is grown in keratinocyte-serum-free medium supplemented with 5 ng/ml epidermal growth factor and 50 µg/ml bovine pituitary extract (Life Technologies, Inc.).

Antibodies and Recombinant Proteins.
FITC-labeled anti-CD44 (Clone G44-26) and PE-labeled CD57 (clone NK-1) were purchased from PharMingen (San Diego, CA). A polyclonal serum (LF37) raised against human ON was a kind gift from Dr. L. W. Fisher (NIH; Ref. 33 ). A mAb (ON-mAb; lot L0122) raised against human platelet ON was purchased from Hematological Technologies, Inc. (Essex Junction, VT). For PSA staining, a polyclonal antibody ({alpha}-PSA) raised against human PSA was purchased from DAKO (Carpinteria, CA). Mouse IgG1, {kappa}-chain (MOPC-21) control was purchased from Sigma (St. Louis, MO). Anti-DIG, a mAb to DIG from mouse-mouse hybrid cells (clone 1.71.256), was purchased from Roche Molecular Biochemicals (Indianapolis, IN). Chinese hamster ovary cells expressing rHevin were a gift from Dr. P. S. Nelson (University of Washington, Seattle, WA). Recombinant ON used in this study was expressed in Escherichia coli (34) .

Cell Separation and Flow Cytometry.
Normal prostate was minced and digested with collagenase (3.0 mg/ml), and three cell populations were separated as described previously (35) . The epithelial fraction was resuspended in 50 µl of 0.1% BSA-PBS solution and 5.0 µl of FITC-labeled anti-CD44 (50 µg/ml) and PE-labeled CD57 (50 µg/ml) were added to 106 cells. After 30 min of incubation at room temperature, the cells were washed with 0.1% BSA-PBS and resuspended in 0.5 ml of 0.1% BSA-PBS. The cells were analyzed by flow cytometry (FACStarplus; Becton Dickinson, San Jose, CA) within 60 min. Gene expression analyses on the sorted cells were done using RT-PCR.

RNA Isolation and Preparation of cDNA Templates.
Total RNA from sorted and cultured cells were isolated using STAT-60 (Tel-Test Inc., Friendswood, TX) according to the manufacturer’s suggested protocol. The quality of the RNA samples was determined by electrophoresis through an agarose gel and staining with ethidium bromide, and the 18S and 28S RNA bands were visualized under UV light. RT of 5 µg of RNA was done in a final volume of 20 µl containing 1x first strand buffer [250 mM Tris-HCl (pH 8.3), 375 mM KCl, and 15 mM MgCl2], 5 mM DTT, 200 units of Moloney murine leukemia virus reverse transcriptase (Life Technologies, Inc.), 10 µM random hexamers, and 10 units of RNase inhibitor (Roche Molecular Biochemicals). A negative RT reaction control tube (lacking-RNA sample) was also included to check for contamination. The samples were incubated at room temperature for 10 min, followed by incubation at 37°C for 1 h. Finally, the RT reaction was terminated by heating at 95°C for 5 min.

Semiquantitative PCR.
Relative quantitation of ON gene expression among different prostate cell lines was done by a method described previously (36) . In the present study, each sample was normalized on the basis of its ß2-MIC content. The MIC gene was selected as an endogenous external control because the prevalence of its transcripts is similar to that of the ON target gene. Briefly, for each primer set (ON and MIC), the optimum amount of input RNA and a linear range of amplification were determined under optimum PCR conditions. Dilution assays were performed to determine the optimum amount of input RNA. The optimum cycle number was determined as the midpoint of the linear range of amplification. All subsequent amplifications were performed by using the optimum cycle number for each primer set. For determining linearity of RNA input versus RT-PCR product output, different dilutions of input RNA ranging from 2.0–8.0 µg were reverse-transcribed and subjected to separate amplification for ON and MIC under optimum cycle number. cDNA was amplified in 50-µl volumes using a thermocycler (Omni Gené, National Labnet Co., Woodbridge, NJ). Reaction mixtures contained 2 mM deoxynucleotide triphosphates, 2 mM MgCl2, 5 pmol of each upstream primer (hON-Us2.0) and downstream primer (hON-Ds2.0), and 2 µl of RT reaction products. PCR cycling conditions consisted of denaturation at 80°C for 3 min, followed by a three-step cycle of denaturation at 95°C (5 s), annealing at 65°C (30 s), and extension at 72°C (30 s). Thirty cycles were carried out before a final 7-min extension period at 72°C. These ON-specific primers yielded a 374-bp PCR-DNA product. For MIC, PCR conditions were 80°C for (3 min), 1 cycle; 95°C (5 s); 69°C (60 s), 28 cycles; and 72°C (7 min), 1 cycle. PCR with MIC-specific primers yields a 550-bp fragment. Under the above conditions, PCR amplification was within the linear range. Aliquots (10.0 µl) of PCR products were resolved by agarose gel electrophoresis. The fluorescent image was captured using an IS-1000 digital imaging system (Alpha Innotech, San Leandro, CA) and analyzed with AlphaEase (Alpha Innotech) software. Briefly, the digital image was analyzed to determine the pixel intensity of each band. Relative quantities of ON mRNA among different cell lines were calculated as the ratio of the ON:MIC pixel intensities from three replicate RT-PCR experiments. Positive results were based on the presence of DNA bands of the expected size. All the PCR-DNA products were validated by dideoxy sequencing of both strands.

Tissues and Histology.
Tissue specimens were obtained from (a) glands resected by radical prostatectomy, (b) organ donors, or (c) "rapid" autopsies conducted within 2–3 h of death. Excess prostatic tissues not needed for pathological diagnosis were obtained from the operating room and used for cell isolation. The histological compositions of these samples were assessed by a pathologist (L. D. T.). Adjacent sections were used in these studies. All the metastatic foci were tested with antibody against PSA. Immunohistochemical labeling for ON is known to vary under different conditions of tissue processing and fixation.5 In this study, we used frozen, formalin-fixed-, or Histochoice-fixed tissues. For frozen sections, tissue samples were snap-frozen in Tissue-Tek OCT (Sakura Finetek USA, Inc, Torrance, CA) by immersing in isopentane (-70°C). The frozen blocks were stored at -80°C. Five-µm sections were cut on a cryostat and mounted on a glass slide. The sections were briefly fixed in acetone and air-dried for 1 h before staining. For paraffin-embedded sections, tissues samples were fixed in either formaldehyde (10% v/v; Mallinckrodt Baker Inc., Paris, KY) or in Histochoice (Bio World Laboratories, Dublin, OH) before embedding in paraffin. Metastatic foci from bone were decalcified in 10% formic acid before being embedded in paraffin. Serial sections of 5.0 µm were cut and mounted on Superfrost Plus slides (VWR Scientific, West Chester, PA). The slides were air-dried at 60°C for 1 h. After deparaffinization in three changes of xylene and clearing in 100% ethanol, slides were hydrated and kept in APK solution (Ventana Medical System, Tucson, AZ) until used for ISH or IHC staining. For IHC using formalin-fixed tissues, antigen retrieval was performed for all slides. Slides were placed in 0.01 M sodium citrate (pH 6.0) and microwaved at full power for 16 min. These slides were allowed to cool for 10 min, washed three times in deionized water, and placed in Tris buffer (pH 7.4) until they were stained. These slides were immediately used for IHC staining.

ISH.
DIG-labeled RNA probes for ON were created as follows. A part of the ON cDNA fragment (454 bp) was PCR-amplified using hOSN.Us3 (5'-ACTGAGGTATCTGTGGGAGCTAATCC-3') and hOSN.Ds2 (5'-CAGTCAGAAGGTTGTTGTCCTCATCC-3') primers. The PCR fragment was cloned into pGEM-T vector (Promega, Madison, WI) and analyzed by sequencing. These plasmids were linearized with Nco1 (for sense probe) and Not1 (for antisense probe). These linearized plasmids were in vitro transcribed with DIG-11-uridine-5'-triphosphate along with 1 unit/µl T7 polymerase and SP6 polymerase. The labeled riboprobes were analyzed and quantitated before use. All enzymes and DIG RNA labeling mix were purchased from Roche Molecular Biochemicals. ISH was performed according to the manufacturer’s protocol on the Ventana genII automated ISH system (Ventana Medical System). ISH for ON was run using preprogrammed recipe files and consisted of a series of steps of buffer rinse, protease digestion, hybridization, detection reactions, and counterstains. DIG-labeled RNA probe was added manually. Anti-DIG was used as a primary antibody. Denaturation was at 80°C, and the hybridization was done at 41°C for 4 h. Washes were performed at 37°C with 2x, 1x, and 0.5x saline sodium citrate. The system uses a mixture of antirabbit and antimouse secondary IgG biotinylated antibody with an indirect biotin avidin diaminobenzidine detection system (Ventana Medical System). Finally, the sections were counterstained with hematoxylin. Appropriate ON-positive (skin tissue) and -negative (with sense probe) controls were processed in parallel.

Western Analysis.
Proteins were separated under reducing conditions on 4–15% PAGE (Bio-Rad Laboratories, Hercules, CA) with 0.1% SDS. Gels were stained with SYPRO Orange protein gel stain (Bio-Rad Laboratories) and photographed. The proteins were then transferred to nitrocellulose membrane (Schleicher and Schuell, Keene, NH) for immunoblotting. The blots were blocked for 1 h with NAP-SureBlocker (Geno Technology, Inc., St. Louis, MO) and then incubated with primary antibody (either 1:500 LF37 or 2.0 µg/ml ON-mAb) in 0.5% gelatin Tween-Tris-buffered saline solution. As a negative controls, identical blots were incubated with nonimmune rabbit serum (1:500) or mouse IgG1, {kappa}-chain (2.0 µg/ml). The nitrocellulose membrane was then incubated with 0.5% gelatin Tween-Tris buffered saline containing 1.5 x 106 cpm/ml 125I-labeled rProtein A (NEN Life Science Products, Inc., Boston, MA) for 1 h at 37°C. Bands were visualized by exposing the immunoblot to Kodak XAR5 film in an X-ray cassette with an intensifying screen (Eastman Kodak, Rochester, NY). Images were acquired using a charged-coupled device camera (Alpha Innotech) and analyzed with PhotoEditor (Microsoft Inc., Redmond, WA).

IHC.
ON was identified using either LF37 or ON-mAb. IHC staining for PSA was performed using the polyclonal antibody {alpha}-PSA. All of the IHC stainings were performed according to the manufacturer’s protocol for the Ventana Nexus automated IHC system (Ventana Medical System). The system uses an indirect biotin-avidin diaminobenzidine detection system. Positive controls were sections of human skin (37 , 38) ; negative controls included replacement of the primary antibody with equal volumes of nonimmune rabbit serum (for LF37) and with nonimmune rabbit IgG1 (for {alpha}-PSA) or equal volumes of mouse IgG1, {kappa}-chain (for ON-mAb). Analysis of ON staining extent for epithelial layers of normal and tumor glands was performed on the entire section. For stroma, at least 10 high-powered areas were counted and averaged. Percentage staining was calculated based on the number of positive cells, irrespective of the staining intensities.


   RESULTS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
ON mRNA Expression in Prostate Cell Lines.
Expression of ON mRNA steady-state levels was studied in various prostate cell lines using semiquantitative RT-PCR. Ratios of ON:MIC signals from three independent replicates were used for quantitation. As shown in Fig. 1Citation , all cell lines, with the exception of DU 145, showed expression of ON mRNA, although the intensity of expression ranged from low to high. Whereas the noninvasive N-PC3 cell line showed moderate expression, as did its parental cell line PC-3, the invasive subline B-PC3 showed high levels of this transcript. ON mRNA was also detected in LNCaP and its sublines, C4, C4-2, and C4-2b, with C4-2b giving the most intense band in this group. In addition, PZ-HPV-7, a cell line derived from normal prostate epithelial cells, shows high levels of ON mRNA. High levels of the transcript were also observed in VeCaPs, the cell line derived from a spine metastasis. These data demonstrate ON expression by eight of nine CaP cell lines, with the most intense expression associated with bone metastatic cell lines.



View larger version (40K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 1. ON gene expression in different prostate cell lines. A, diagrammatic illustration of hON gene and cDNA. Only the hON coding sequence is drawn to scale. The cDNA was amplified by 30 cycles using upstream primer hON-Us2.0 (5'-CGAAG-AGGAGGTGGTGGCGGAAA-A-3') and downstream primer hON-Ds2.0 (5'-GGTTGTTG-TCCTCATCCCTCTCATAC-3'). Also shown is the region from the open reading frame (ORF) of the cDNA used as a probe in ISH. MIC was used as a control and was amplified using primers Mic3 (5'-TGA-CCAAGATGTTGATGTTGGATAAGAG-3') and Mic5 (5'-CACGTCATCCAGCAG AGA ATGGAAAGTC-3'). B, gel showing representative results obtained in three independent replicate experiments of RT-PCR for ON gene expression. Total RNA from different cell lines was reverse-transcribed and PCR-amplified using ON and MIC primers as described in "Materials and Methods." An aliquot of each PCR-DNA was electrophoresed on a 1.5% agarose gel and visualized with ethidium bromide. Lane 1, molecular weight marker (100-bp ladder; Life Technologies, Inc.); Lanes 2–11, different prostate cell lines. Lane 12, negative control (no RNA during reverse transcription). C, differential expression of ON mRNA in various prostate cell lines. Each data point represents the mean ±SE obtained from three replicate RT-PCRs.

 
Specificity of the Antibodies.
To clarify the specificity of the antibodies used in this study, Western blot analyses were done using rHevin. No cross-reaction was observed between LF37/ON-mAb and the ON-like protein rHevin (Fig. 2)Citation .



View larger version (73K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 2. Specificity of the antibodies. Western blot analyses (top) of ON and its closely related protein, hevin, were performed using LF37 (A) and ON-mAb (B). Lane 1, conditioned media containing rHevin (12.0 µl); Lane 2, lysate from Chinese hamster ovary cells that expresses rHevin (12.0 µl); Lane 3, purified rON. Bottom, a photograph of the SDS-PAGE stained with SYPRO Orange.

 
ON Expression in Normal Prostate versus CaP Tissues.
To investigate the expression and location of ON in tissues, ISH and IHC were performed on normal prostate and CaP specimens. Because CaP is histologically heterogeneous and often multifocal within the prostate (39 , 40) we compared ON expression in normal areas as well in the neoplastic areas of the same prostate (matched pairs). The results of ON immunoreactivity are summarized in Table 1Citation . In normal prostate, glandular epithelium shows low to moderate levels of ON immunoreactivity in both luminal and basal cells. In addition, cell-specific RT-PCR showed the presence of the ON transcript in both luminal cells and basal cells (Fig. 3)Citation . Immunoreactivity was observed in tumor cells from three CaP cases (3 of 10). Weak staining was also observed in fibromuscular stromal cells of both normal and tumor glands.


View this table:
[in this window]
[in a new window]

  		Table 1 ON immunoreactivity in matched pairs of prostatic tissue (normal versus tumor): tabulation of immunohistochemically defined expression of ON in samples of prostate cancer and paired nonneoplastic tissue

 


View larger version (52K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 3. Cellular origin of ON gene expression in a normal prostate. Basal and luminal cells from normal prostate tissue were separated by flow cytometry using FITC-labeled CD44 (basal) and PE-labeled CD57 (luminal) cell surface markers. RNA isolated from the sorted cells was used to determine the relative steady-state levels of ON mRNA with RT-PCR using ON-specific primers (inset). {alpha}2-Microglobulin (MIC) was used as a control.

 
ON Expression in Primary CaP and Its Specific Distant Metastatic Sites.
To assess the possible association between ON expression and tumor progression, we analyzed primary CaP with its specific lymph node metastatic site. The results of ON immunopositivity are summarized in Table 2Citation . In general, low to moderate ON immunoreactivity is seen in the primary cancer cells. The corresponding lymph node metastatic samples showed a moderate to strong ON signal within the tumor mass.


View this table:
[in this window]
[in a new window]

  		Table 2 ON immunoreactivity in primary prostate and its specific metastatic lesions

 
ON Expression in CaP Metastatic Tissues.
We also analyzed CaP metastases from different tissues to assess the possible association of ON expression with tumor progression. Metastases that we analyzed included sites from the bone, liver, lymph, lungs, colon, and urinary bladder (Table 3)Citation . In metastatic foci, two histological patterns of tumor were observed: (a) sheets of tumor cells that did not form glands (denoted in Table 3Citation as "sheets"); and (b) aggregates of tumor cells that formed glandular structures (denoted in Table 3Citation as "glandular"). Serial sections of metastatic foci were analyzed for PSA and ON expression. ISH analysis showed high levels of ON mRNA in the cytoplasm of the tumor cells (Fig. 4)Citation . As shown in Fig. 5Citation , PSA immunoreactivity was intense and homogenous in the tumor cells from different metastatic sites. Most metastatic foci showed elevated levels of ON expression, although areas of intense and weak immunostaining were frequently observed in the same foci. Generally, intense ON staining was observed in metastatic foci from bone (Fig. 5-2cCitation ), whereas a diffuse pattern was observed in soft tissue metastasis. In soft tissue metastasis, increased immunoreactivity was observed in tumor cells adjacent to normal tissue (arrow, Fig. 5-4cCitation ).


View this table:
[in this window]
[in a new window]

  		Table 3 ON immunoreactivity in metastatic lesions

 


View larger version (113K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 4. ON mRNA expression determined by tissue ISH using an ON-specific RNA probe. ISH staining was performed on serial sections of formalin-fixed or Histochoice-fixed and paraffin-embedded metastatic tissues as described in "Materials and Methods." A representative CaP metastatic foci from bone (top) and lymph node (bottom) are shown. In b (original magnification, x200) and c (higher magnification of b, x400), intensely positive brown hybridization signals are seen in the tumor cells (Tu). Residual bone (Bo) also can be seen in bone metastasis. In lymph node metastasis, ON gene expression was heterogeneous with both positive (open arrow) and negative (closed arrow) staining cells. Specific hybridization signal with antisense probe in the endothelial cells lining the vessel wall (arrowhead) confirm the integrity of cell mRNA and the specificity of hybridization conditions. Necrotic areas (Ne) within the tumor did not express ON. Negative controls were carried out on parallel sections with sense probe (a, original magnification, x200).

 


View larger version (130K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 5. Immunolocalization of ON in various CaP metastatic tissues. A representative of IHC staining of different CaP metastatic sites is shown, including one site each from soft tissue (1), bone (2), urinary bladder (3), lung (4), and liver (5). Serial sections from each tissue were stained with mouse IgG1,{kappa}-chain (a), {alpha}-PSA (b), and ON-mAb (c) as described in "Materials and Methods." Positive (brown) staining was observed in all metastatic foci (original magnification, x200). A low level of staining was observed in the smooth muscle of urinary bladder (3c). Increased expression of ON immunoreactivity was observed in invading tumor (arrow in 4C). Tu, tumor cells; Bo, bone; He, hepatocyte.

 

   DISCUSSION
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
Invasion and metastasis involve multiple steps, which are not well characterized at the molecular and cellular levels. The initial steps involved in invasion and metastasis by a tumor cell include the breakdown of cell-cell junctions, dissociation of tumor cells, focal proteolysis of the ECM, and dissemination through neovascularization (24) . Recent investigations have identified possible participants in the acquisition of metastatic potential by cancer cells. These include adhesive and/or antiadhesive molecules, proteases, and angiogenic factors. Alterations in the expression pattern of several genes involved in cell attachment have been studied in CaP. These include cadherins (41, 42, 43, 44, 45) , integrins (46, 47, 48, 49, 50, 51, 52) , laminin 5 (53 , 54) , hevin (55) , and CD44 (56, 57, 58) . In the current study, we examined the prototypic antiadhesive protein ON. We report here a detailed analysis of ON expression in malignant as well as normal prostate specimens. The role of ON in neoplastic growth and progression is speculative. It may include (a) modulation of cell-cell interaction, (b) remodeling of ECM via the induction of proteolytic enzymes, and (c) the enhancement of tumor-associated angiogenesis. Some of these biological activities may be triggered by the release of distinct domains of ON by prostate-associated serine proteases such as hK2.

At the light microscope level, alterations in cell-cell and cell-matrix adhesion in tumors are reflected in the degree of cohesiveness and the pattern of tumor growth. Loss of normal cell adhesion properties plays a key role in the progression of cancer. This alteration in tumor cell adhesion is important because detachment of tumor cells is an early step in the invasion of surrounding tissues and metastasis to secondary sites. In vitro studies have shown that introduction of exogenous ON to cultured cells inhibits cell spreading and induces cellular rounding, which results in the detachment of cells (59) . Overexpression of ON in stably transfected F9 embryonal carcinoma cell lines results in aggregation and rounding (60) . ON may alter these cellular morphologies and cell-cell or cell-matrix interactions by disrupting cell-substrate links and promoting the rearrangement of actin cytoskeletal elements (61) . Down-regulation of ON by antisense ON suppresses and abolishes the tumorigenic potential of human melanoma cells (26) . This down-regulation is accompanied by reduced adhesive and invasive capacities in vitro.

Pericellular degradation of the matrix component is an essential requirement for the motility of the tumor cells from their primary site. Studies have shown that ON, at physiological concentrations, can induce the expression of MMPs (62) including collagenase, stromelysin, and Mr 92,000 gelatinase, suggesting that ON may alter the nature of the ECM presented to the cell. Studies with synthetic peptides representing unique sequence motifs from the different domains of ON have shown that ON peptides can increase the levels of MMPs (63) and plasminogen activator inhibitor 1 (16 , 64) , as well as decrease ECM synthesis (65) . This was further confirmed by a recent finding that there is a significant increase in MMP-2 activity in CaP cell lines exposed to ON (66) . Thus, the secretion of this protein by tumor cells and/or surrounding stromal cells may result in the focal proteolysis of the ECM. This may facilitate local invasion and the subsequent distant spread of tumor cells.

Finally, the establishment and growth of tumors at secondary sites require angiogenesis. An "angiogenic switch" has been associated with active tumorigenesis (67) . Several studies have implicated the role of ON in the modulation of angiogenesis (10 , 17 , 18 , 27) . Expression of ON is induced in endothelial cells during angiogenesis (65) . The addition of exogenous ON to endothelial cells in culture results in a 4-fold decrease in thromospondin, an inhibitor of angiogenesis (64) . In vivo studies using synthetic Cu2+-binding peptides designed from data derived from ON protease digestion stimulate angiogenesis (17) . It is conceivable that ON cleavage by serine proteases of prostate cancer cells and the consequent release of functionally distinct fragments could account for the pleotropic actions of ON. Earlier studies documented that this type of unmasking of biological functions distinct from those observed in the native protein after specific cleavage occurs in laminin 5 (68) , osteopontin (69) , and fibronectin (70) .

In summary, we document here the first evidence of ON expression in CaP cell lines and tissues. Our data further reveal an apparent up-regulation of ON mRNA and protein expression in the cell lines and tissues identified with bone metastasis. These observations are in full concurrence with the hypothesis that osseous metastatic CaP cells must be osteomimetic, which allows the cells to thrive in bone (71) . Although we did not address the expression of ON in association with Gleason grade, such studies are necessary and are under way. Finally, one of the more interesting aspects under study is whether the proteolysis of ON by hK2 contributes to the unique biological responses seen in CaP bone metastases (e.g., the osteoblastic reaction).


   ACKNOWLEDGMENTS
 
We thank Lisha G. Brown for tissue culture and Kent R. Buhler for the excellent technical assistance in Western blot analyses. We also thank Lan L. Nguyen for initial PCR studies.


   FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 Supported by The Fresno Foundations, CaP CURE Foundations, The Richard M. Lucas Foundation, and The National Institute of Diabetes and Digestive and Kidney Diseases O’Brien Center Award (Grant #2P50DK47656-06). Back

2 To whom requests for reprints should be addressed, at HSB I 340, Mail stop 356510, University of Washington, Seattle, WA 98195. Phone: (206) 543 1461; Fax: (206) 543 1146; E-mail: Regit{at}u.washington.edu Back

3 The abbreviations used are: ECM, extracellular matrix; ON, osteonectin; mAb, monoclonal antibody; RT, reverse transcription; DIG, digoxigenin; ISH, in situ hybridization; IHC, immunohistochemistry; CaP, prostate cancer; PSA, prostate-specific antigen; MIC, microglobulin; rHevin, recombinant Hevin; MMP, matrix metalloprotease; hON, human ON; PE, phycoerythrin. Back

4 Unpublished observations. Back

5 J. Bassuk, unpublished observations.

Received 6/21/99; revised 12/ 7/99; accepted 12/20/99.


   REFERENCES
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Girard J. P., Springer T. A. Cloning from purified high endothelial venule cells of hevin, a close relative of the antiadhesive extracellular matrix protein SPARC. Immunity, 2: 113-123, 1995.[CrossRef][Medline]
  2. Johnston I. G., Paladino T., Gurd J. W., Brown I. R. Molecular cloning of SC1: a putative brain extracellular matrix glycoprotein showing partial similarity to osteonectin/BM40/SPARC. Neuron, 4: 165-176, 1990.[CrossRef][Medline]
  3. Guermah M., Crisanti P., Laugier D., Dezelee P., Bidou L., Pessac B., Calothy G. Transcription of a quail gene expressed in embryonic retinal cells is shut off sharply at hatching. Proc. Natl. Acad. Sci. USA, 88: 4503-4507, 1991.[Abstract/Free Full Text]
  4. Zwijsen A., Blockx H., Van Arnhem W., Willems J., Fransen L., Devos K., Raymackers J., Van de Voorde A., Slegers H. Characterization of a rat C6 glioma-secreted follistatin-related protein (FRP). Cloning and sequence of the human homologue. Eur. J. Biochem., 225: 937-946, 1994.[Medline]
  5. Alliel P. M., Perin J. P., Jolles P., Bonnet F. J. Testican, a multidomain testicular proteoglycan resembling modulators of cell social behaviour. Eur. J. Biochem., 214: 347-350, 1993.[Medline]
  6. Termine J. D., Kleinman H. K., Whitson S. W., Conn K. M., McGarvey M. L., Martin G. R. Osteonectin, a bone-specific protein linking mineral to collagen. Cell, 26: 99-105, 1981.[CrossRef][Medline]
  7. Mason I. J., Murphy D., Munke M., Francke U., Elliott R. W., Hogan B. L. Developmental and transformation-sensitive expression of the Sparc gene on mouse chromosome 11. EMBO J., 5: 1831-1837, 1986.[Medline]
  8. Soderling J. A., Reed M. J., Corsa A., Sage E. H. Cloning and expression of murine SC1, a gene product homologous to SPARC. J. Histochem. Cytochem., 45: 823-835, 1997.[Abstract/Free Full Text]
  9. Iruela-Arispe M. L., Lane T. F., Redmond D., Reilly M., Bolender R. P., Kavanagh T. J., Sage E. H. Expression of SPARC during development of the chicken chorioallantoic membrane: evidence for regulated proteolysis in vivo.. Mol. Biol. Cell, 6: 327-343, 1995.[Abstract]
  10. Kupprion C., Motamed K., Sage E. H. SPARC (BM-40, osteonectin) inhibits the mitogenic effect of vascular endothelial growth factor on microvascular endothelial cells. J. Biol. Chem., 273: 29635-29640, 1998.[Abstract/Free Full Text]
  11. Pichler R. H., Bassuk J. A., Hugo C., Reed M. J., Eng E., Gordon K. L., Pippin J., Alpers C. E., Couser W. G., Sage E. H., Johnson R. J. SPARC is expressed by mesangial cells in experimental mesangial proliferative nephritis and inhibits platelet-derived-growth-factor-medicated mesangial cell proliferation in vitro.. Am. J. Pathol., 148: 1153-1167, 1996.[Abstract]
  12. Sage E. H., Bassuk J. A., Yost J. C., Folkman M. J., Lane T. F. Inhibition of endothelial cell proliferation by SPARC is mediated through a Ca(2+)-binding EF-hand sequence. J. Cell Biochem., 57: 127-140, 1995.[CrossRef][Medline]
  13. Strandjord T. P., Sage E. H., Clark J. G. SPARC participates in the branching morphogenesis of developing fetal rat lung. Am. J. Respir. Cell Mol. Biol., 13: 279-287, 1995.[Abstract]
  14. Latvala T., Puolakkainen P., Vesaluoma M., Tervo T. Distribution of SPARC protein (osteonectin) in normal and wounded feline cornea. Exp. Eye Res., 63: 579-584, 1996.[CrossRef][Medline]
  15. Kelm, R. J., Jr., Swords, N. A., Orfeo, T., and Mann, K. G. Osteonectin in matrix remodeling. A plasminogen-osteonectin-collagen complex. J. Biol. Chem., 269: 30147–30153, 1994.
  16. Hasselaar P., Sage E. H. SPARC antagonizes the effect of basic fibroblast growth factor on the migration of bovine aortic endothelial cells. J. Cell Biochem., 49: 272-283, 1992.[CrossRef][Medline]
  17. Lane, T. F., Iruela Arispe, M. L., Johnson, R. S., and Sage, E. H. SPARC is a source of copper-binding peptides that stimulate angiogenesis. J. Cell Biol., 125: 929–943, 1994.
  18. Kraemer M., Tournaire R., Dejong V., Montreau N., Briane D., Derbin C., Binetruy B. Rat embryo fibroblasts transformed by c-jun display highly metastatic and angiogenic activities in vivo and deregulate gene expression of both angiogenic and antiangiogenic factors. Cell Growth Differ., 10: 193-200, 1999.[Abstract/Free Full Text]
  19. Bassuk J. A., Birkebak T., Rothmier J. D., Clark J. M., Bradshaw A., Muchowski P. J., Howe C. C., Clark J. I., Sage E. H. Disruption of the Sparc locus in mice alters the differentiation of lenticular epithelial cells and leads to cataract formation. Exp. Eye Res., 68: 321-331, 1999.[CrossRef][Medline]
  20. Lane T. F., Sage E. H. Functional mapping of SPARC: peptides from two distinct Ca+(+)-binding sites modulate cell shape. J. Cell Biol., 111: 3065-3076, 1990.[Abstract/Free Full Text]
  21. Bellahcene A., Castronovo V. Increased expression of osteonectin and osteopontin, two bone matrix proteins, in human breast cancer. Am. J. Pathol., 146: 95-100, 1995.[Abstract]
  22. Porte H., Chastre E., Prevot S., Nordlinger B., Empereur S., Basset P., Chambon P., Gespach C. Neoplastic progression of human colorectal cancer is associated with overexpression of the stromelysin-3 and BM-40/SPARC genes. Int. J. Cancer, 64: 70-75, 1995.[Medline]
  23. Massi D., Franchi A., Borgognoni L., Reali U. M., Santucci M. Osteonectin expression correlates with clinical outcome in thin cutaneous malignant melanomas. Hum. Pathol., 30: 339-344, 1999.[CrossRef][Medline]
  24. Porte H., Triboulet J. P., Kotelevets L., Carrat F., Pr’evot S., Nordlinger B., DiGioia Y., Wurtz A., Comoglio P., Gespach C., Chastre E. Overexpression of stromelysin-3, BM-40/SPARC, and MET genes in human esophageal carcinoma: implications for prognosis. Clin. Cancer Res., 4: 1375-1382, 1998.[Abstract]
  25. Rempel S. A., Ge S., Gutierrez J. A. SPARC: a potential diagnostic marker of invasive meningiomas. Clin. Cancer Res., 5: 237-241, 1999.[Abstract/Free Full Text]
  26. Ledda M. F., Adris S., Bravo A. I., Kairiyama C., Bover L., Chernajovsky Y., Mordoh J., Podhajcer O. L. Suppression of SPARC expression by antisense RNA abrogates the tumorigenicity of human melanoma cells. Nat. Med., 3: 171-176, 1997.[CrossRef][Medline]
  27. Sage E. H. Terms of attachment: SPARC and tumorigenesis. Nat. Med., 3: 144-146, 1997.[CrossRef][Medline]
  28. Le Bail B., Faouzi S., Boussarie L., Guirouilh J., Blanc J. F., Carles J., Bioulac-Sage P., Balabaud C., Rosenbaum J. Osteonectin/SPARC is overexpressed in human hepatocellular carcinoma. J. Pathol., 189: 46-52, 1999.[CrossRef][Medline]
  29. Stone K. R., Mickey D. D., Wunderli H., Mickey G. H., Paulson D. F. Isolation of a human prostate carcinoma cell line (DU 145). Int. J. Cancer, 21: 274-281, 1978.[Medline]
  30. Kaighn, M. E., Shankar Narayan, K., Ohnuki, Y., Lechner, J. F., and Jones, L. W. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Investig. Urol., 17: 16–23, 1979.
  31. Horoszewicz J. S., Leong S. S., Chu T. M., Wajsman Z. L., Friedman M., Papsidero L., Kim U., Chai L. S., Kakati S., Arya S. K., Sandberg A. A. The LNCaP cell line—a new model for studies on human prostatic carcinoma. Prog. Clin. Biol. Res., 32: 115-132, 1980.
  32. Thalmann G. N., Anezinis P. E., Chang S., Zhau H. E., Kim E. E., Hopwood V. L., Pathak S., von Eschenbach A. C., Chung L. W. K. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res., 54: 2577-2581, 1994.[Abstract/Free Full Text]
  33. Fisher, L. W., Stubbs, J. T., III, and Young, M. F. Antisera and cDNA probes to human and certain animal model bone matrix noncollagenous proteins. Acta. Orthop. Scand., 5(Suppl.): 61–65, 1995.
  34. Bassuk J. A., Baneyx F., Vernon R. B., Funk S. E., Sage E. H. Expression of biologically active human SPARC in Escherichia coli.. Arch. Biochem. Biophys., 325: 8-19, 1996.[CrossRef][Medline]
  35. Liu A. Y., True L. D., LaTray L., Nelson P. S., Ellis W. J., Vessella R. L., Lange P. H., Hood L., Van Den Engh G. Cell/cell interaction in prostate gene regulation and cytodifferentiation. Proc. Natl. Acad. Sci. USA, 94: 10705-10710, 1997.[Abstract/Free Full Text]
  36. Thomas R., Anderson W. A., Raman V., Reddi A. H. Androgen-dependent gene expression of bone morphogenetic protein 7 in mouse prostate. Prostate, 37: 236-245, 1998.[CrossRef][Medline]
  37. Porter P. L., Sage E. H., Lane T. F., Funk S. E., Gown A. M. Distribution of SPARC in normal and neoplastic human tissue. J. Histochem. Cytochem., 43: 791-800, 1995.[Abstract]
  38. Hunzelmann N., Hafner M., Anders S., Krieg T., Nischt R. BM-40 (osteonectin, SPARC) is expressed both in the epidermal and in the dermal compartment of adult human skin. J. Investig. Dermatol., 110: 122-126, 1998.[CrossRef][Medline]
  39. Ware J. L. Prostate cancer progression. Implications of histopathology. Am. J. Pathol., 145: 983-993, 1994.[Abstract]
  40. Macintosh C. A., Stower M., Reid N., Maitland N.J. Precise microdissection of human prostate cancers reveals genotypic heterogeneity. Cancer Res., 58: 23-28, 1998.[Abstract/Free Full Text]
  41. Umbas R., Isaacs W. B., Bringuier P. P., Schaafsma H., Karthaus H., Oosterhof G., Debruyne F., Schalken J. Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res., 54: 3929-3933, 1994.[Abstract/Free Full Text]
  42. Umbas R., Schalken J. A., Aalders T. W., Carter B. S., Karthaus H. F. M., Schaafsma H. E., Debruyne F. M. J., Isaacs W. B. Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer. Cancer Res., 52: 5104-5109, 1992.[Abstract/Free Full Text]
  43. Morton, R. A., Jr., Ewing, C. M., Watkins, J. J., and Isaacs, W. B. The E-cadherin cell-cell adhesion pathway in urologic malignancies. World J. Urol., 13: 364–368, 1995.
  44. Cheng L., Nagabhushan M., Pretlow T. P., Amini S. B., Pretlow T. G. Expression of E-cadherin in primary and metastatic prostate cancer. Am. J. Pathol., 148: 1375-1380, 1996.[Abstract]
  45. De M. A., Knudsen B., Chan-Tack K., Epstein J. I. E-cadherin expression as a marker of tumor aggressiveness in routinely processed radical prostatectomy specimens. Urology, 53: 707-713, 1999.[CrossRef][Medline]
  46. Bonkhoff H., Stein U., Remberger K. Differential expression of {alpha}6 and {alpha}2 very late antigen integrins in the normal, hyperplastic, and neoplastic prostate: simultaneous demonstration of cell surface receptors and their extracellular ligands. Hum. Pathol., 24: 243-248, 1993.[CrossRef][Medline]
  47. Knox J. D., Cress A. E., Clark V., Manriquez L., Affinito K. S., Dalkin B. L., Nagle R. B. Differential expression of extracellular matrix molecules and the {alpha}6-integrins in the normal and neoplastic prostate. Am. J. Pathol., 145: 167-174, 1994.[Abstract]
  48. Fornaro M., Tallini G., Bofetiado C. J., Bosari S., Languino L. R. Down-regulation of ß1C integrin, an inhibitor of cell proliferation, in prostate carcinoma. Am. J. Pathol., 149: 765-773, 1996.[Abstract]
  49. Allen M. V., Smith G. J., Juliano R., Maygarden S. J., Mohler J. L. Downregulation of the ß4 integrin subunit in prostatic carcinoma and prostatic intraepithelial neoplasia. Hum. Pathol., 29: 311-318, 1998.[CrossRef][Medline]
  50. Trikha M., Timar J., Lundy S. K., Szekeres K., Tang K., Grignon D., Porter A. T., Honn K. V. Human prostate carcinoma cells express functional {alpha}IIb(ß)3 integrin. Cancer Res., 56: 5071-5078, 1996.[Abstract/Free Full Text]
  51. Trikha M., Raso E., Cai Y., Fazakas Z., Paku S., Porter A. T., Timar J., Honn K. V. Role of {alpha}II(b)ß3 integrin in prostate cancer metastasis. Prostate, 35: 185-192, 1998.[CrossRef][Medline]
  52. Zheng D. Q., Woodard A. S., Fornaro M., Tallini G., Languino L. R. Prostatic carcinoma cell migration via {alpha}(v)ß3 integrin is modulated by a focal adhesion kinase pathway. Cancer Res., 59: 1655-1664, 1999.[Abstract/Free Full Text]
  53. Hao J., Yang Y., McDaniel K. M., Dalkin B. L., Cress A. E., Nagle R. B. Differential expression of laminin 5 ({alpha}3 ß3 {gamma}2) by human malignant and normal prostate. Am. J. Pathol., 149: 1341-1349, 1996.[Abstract]
  54. Pfohler C., Fixemer T., Jung V., Dooley S., Remberger K., Bonkhoff H. In situ hybridization analysis of genes coding collagen IV {alpha}1 chain, laminin ß1 chain, and S-laminin in prostate tissue and prostate cancer: increased basement membrane gene expression in high-grade and metastatic lesions. Prostate, 36: 143-150, 1998.[CrossRef][Medline]
  55. Nelson P. S., Plymate S. R., Wang K., True L. D., Ware J. L., Gan L., Liu A. Y., Hood L. Hevin, an antiadhesive extracellular matrix protein, is downregulated in metastatic prostate adenocarcinoma. Cancer Res., 58: 232-236, 1998.[Abstract/Free Full Text]
  56. Gao A. C., Lou W., Dong J., Isaacs J. T. CD44 is a metastasis suppressor gene for prostatic cancer located on human chromosome 11p13. Cancer Res., 57: 846-849, 1997.[Abstract/Free Full Text]
  57. Takahashi S., Kimoto N., Orita S., Cui L., Sakakibara M., Shirai T. Relationship between CD44 expression and differentiation of human prostate adenocarcinomas. Cancer Lett., 129: 97-102, 1998.[CrossRef][Medline]
  58. Paradis V., Eschwege P., Loric S., Dumas F., Ba N., Benoit G., Jardin A., Bedossa P. De novo expression of CD44 in prostate carcinoma is correlated with systemic dissemination of prostate cancer. J. Clin. Pathol., 51: 798-802, 1998.[Abstract]
  59. Murphy-Ullrich J. E., Lane T. F., Pallero M. A., Sage E. H. SPARC mediates focal adhesion disassembly in endothelial cells through a follistatin-like region and the Ca(2+)-binding EF-hand. J. Cell Biochem., 57: 341-350, 1995.[CrossRef][Medline]
  60. Everitt E. A., Sage E. H. Overexpression of SPARC in stably transfected F9 cells mediates attachment and spreading in Ca(2+)-deficient medium. Biochem. Cell Biol., 70: 1368-1379, 1992.[Medline]
  61. Tremble P. M., Lane T. F., Sage E. H., Werb Z. SPARC, a secreted protein associated with morphogenesis and tissue remodeling, induces expression of metalloproteinases in fibroblasts through a novel extracellular matrix-dependent pathway. J. Cell Biol., 121: 1433-1444, 1993.[Abstract/Free Full Text]
  62. Gilles C., Bassuk J. A., Pulyaeva H., Sage E. H., Foidart J. M., Thompson E. W. SPARC/osteonectin induces matrix metalloproteinase 2 activation in human breast cancer cell lines. Cancer Res., 58: 5529-5536, 1998.[Abstract/Free Full Text]
  63. Shankavaram U. T., DeWitt D. L., Funk S. E., Sage E. H., Wahl L. M. Regulation of human monocyte matrix metalloproteinases by SPARC. J. Cell Physiol., 173: 327-334, 1997.[CrossRef][Medline]
  64. Lane, T. F., Iruela Arispe, M. L., and Sage, E. H. Regulation of gene expression by SPARC during angiogenesis in vitro. Changes in fibronectin, thrombospondin-1, and plasminogen activator inhibitor-1. J. Biol. Chem., 267: 16736–16745, 1992.
  65. Iruela Arispe, M. L., Hasselaar, P., and Sage, H. Differential expression of extracellular proteins is correlated with angiogenesis in vitro. Lab. Investig., 64: 174–186, 1991.
  66. Jacob K., Webber M., Benayahu D., Kleinman H. K. Osteonectin promotes prostate cancer cell migration and invasion: a possible mechanism for metastasis to bone. Cancer Res., 59: 4453-4457, 1999.[Abstract/Free Full Text]
  67. Hanahan D., Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell, 86: 353-364, 1996.[CrossRef][Medline]
  68. Giannelli, G., Falk-Marzillier, J., Schiraldi, O., Stetler-Stevenson, W. G., and Quaranta, V. Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5. Science (Washington, DC), 277: 225–228, 1997.
  69. Senger D. R., Perruzzi C. A. Cell migration promoted by a potent GRGDS-containing thrombin-cleavage fragment of osteopontin. Biochim. Biophys. Acta, 1314: 13-24, 1996.[Medline]
  70. Kochevar G. J., Stanek J. A., Rucker E. B. Truncated fibronectin. An autologous growth-promoting substance secreted by renal carcinoma cells. Cancer (Phila.), 69: 2311-2315, 1992.[CrossRef][Medline]
  71. Koeneman K. S., Yeung F., Chung L. W. Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate, 39: 246-261, 1999.[CrossRef][Medline]



This article has been cited by other articles:


Home page
 Mol Cancer ResHome page
K. Chu, C.-J. Cheng, X. Ye, Y.-C. Lee, A. J. Zurita, D.-T. Chen, L.-Y. Yu-Lee, S. Zhang, E. T. Yeh, M. C-T. Hu, et al.
Cadherin-11 Promotes the Metastasis of Prostate Cancer Cells to Bone
Mol. Cancer Res., August 1, 2008; 6(8): 1259 - 1267.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
N. Chen, X.-C. Ye, K. Chu, N. M. Navone, E. H. Sage, L.-Y. Yu-Lee, C. J. Logothetis, and S.-H. Lin
A Secreted Isoform of ErbB3 Promotes Osteonectin Expression in Bone and Enhances the Invasiveness of Prostate Cancer Cells
Cancer Res., July 15, 2007; 67(14): 6544 - 6548.
[Abstract] [Full Text] [PDF]

Home page
 BioinformaticsHome page
P. Qiu, Z. J. Wang, K. J. R. Liu, Z.-Z. Hu, and C. H. Wu
Dependence network modeling for biomarker identification
Bioinformatics, January 15, 2007; 23(2): 198 - 206.
[Abstract] [Full Text] [PDF]

Home page
 J. Nutr.Home page
R. Handayani, L. Rice, Y. Cui, T. A. Medrano, V. G. Samedi, H. V. Baker, N. J. Szabo, and K. T. Shiverick
Soy Isoflavones Alter Expression of Genes Associated with Cancer Progression, Including Interleukin-8, in Androgen-Independent PC-3 Human Prostate Cancer Cells
J. Nutr., January 1, 2006; 136(1): 75 - 82.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Y. Ikuta, T. Nakatsura, T. Kageshita, S. Fukushima, S. Ito, K. Wakamatsu, H. Baba, and Y. Nishimura
Highly Sensitive Detection of Melanoma at an Early Stage Based on the Increased Serum Secreted Protein Acidic and Rich in Cysteine and Glypican-3 Levels
Clin. Cancer Res., November 15, 2005; 11(22): 8079 - 8088.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. W. Nyman, K. J. Campbell, E. Hersh, K. Long, K. Richardson, V. Trieu, N. Desai, M. J. Hawkins, and D. D. Von Hoff
Phase I and Pharmacokinetics Trial of ABI-007, a Novel Nanoparticle Formulation of Paclitaxel in Patients With Advanced Nonhematologic Malignancies
J. Clin. Oncol., November 1, 2005; 23(31): 7785 - 7793.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. N. Rich, C. Hans, B. Jones, E. S. Iversen, R. E. McLendon, B.K. A. Rasheed, A. Dobra, H. K. Dressman, D. D. Bigner, J. R. Nevins, et al.
Gene Expression Profiling and Genetic Markers in Glioblastoma Survival
Cancer Res., May 15, 2005; 65(10): 4051 - 4058.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
W.-C. Huang, Z. Xie, H. Konaka, J. Sodek, H. E. Zhau, and L. W.K. Chung
Human Osteocalcin and Bone Sialoprotein Mediating Osteomimicry of Prostate Cancer Cells: Role of cAMP-Dependent Protein Kinase A Signaling Pathway
Cancer Res., March 15, 2005; 65(6): 2303 - 2313.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
B. S. Parker, P. Argani, B. P. Cook, H. Liangfeng, S. D. Chartrand, M. Zhang, S. Saha, A. Bardelli, Y. Jiang, T. B. St. Martin, et al.
Alterations in Vascular Gene Expression in Invasive Breast Carcinoma
Cancer Res., November 1, 2004; 64(21): 7857 - 7866.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. I. Koukourakis, A. Giatromanolaki, R. A. Brekken, E. Sivridis, K. C. Gatter, A. L. Harris, and E. H. Sage
Enhanced Expression of SPARC/Osteonectin in the Tumor-associated Stroma of Non-Small Cell Lung Cancer Is Correlated with Markers of Hypoxia/ Acidity and with Poor Prognosis of Patients
Cancer Res., September 1, 2003; 63(17): 5376 - 5380.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. N. Rich, Q. Shi, M. Hjelmeland, T. J. Cummings, C.-T. Kuan, D. D. Bigner, C. M. Counter, and X.-F. Wang
Bone-related Genes Expressed in Advanced Malignancies Induce Invasion and Metastasis in a Genetically Defined Human Cancer Model
J. Biol. Chem., April 25, 2003; 278(18): 15951 - 15957.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page